
Stocks Market
Sothema Acquires Ramo Pharm to Expand Consumer Health and Wellness Portfolio
Moroccan pharmaceutical leader Sothema has signed a landmark agreement to fully acquire Ramo Pharm, marking a key milestone in its diversification strategy. This move, coming just ten months after the acquisition of Soludia Maghreb, aims to bolster Sothema's presence in the rapidly growing consumer health and dietary supplements market. The acquisition aligns with the group's vision to build a robust, multi-pillar healthcare portfolio, bridging the gap between specialized treatments and everyday wellness both locally and internationally, pending regulatory approvals.
Listen to this article
Unlock audio versions of premium articles and more with a Pro subscription.
Strategic Expansion in Consumer Health
The Moroccan pharmaceutical group Sothema, listed on the Casablanca Stock Exchange, has announced the signing of a definitive agreement to acquire 100% of the capital of Ramo Pharm. This strategic move marks a significant milestone in the group's external growth strategy, focusing heavily on the high-potential consumer health and wellness sectors.
This acquisition comes just ten months after Sothema successfully integrated Soludia Maghreb, a transaction that successfully strengthened the group's footprint in renal care and dialysis. By adding Ramo Pharm to its portfolio, Sothema aims to capture a larger share of the growing Moroccan and international markets for dietary supplements, preventive health, and daily wellness products.
A Complementary Four-Pillar Portfolio
With this new integration, Sothema continues to diversify its therapeutic offerings, which are now structured around four core business pillars designed to generate synergies and sustainable growth:
- General Medicine & Chronic Care: The historical foundation of the group, focusing on common illnesses and long-term chronic conditions.
- Specialty Products: High-value specialized treatments, including advanced therapies in oncology.
- Dialysis & Renal Care: Specialized renal support services and products, bolstered by the previous integration of Soludia Maghreb.
- Wellness & Consumer Health: Daily health products, vitamins, and dietary supplements, set to be the primary growth driver following the acquisition of Ramo Pharm.
Leadership Vision and Regulatory Steps
Lamia Tazi, Chief Executive Officer of Sothema, emphasized that the acquisition aligns with their patient-centric vision: "We are convinced that the future of a healthcare group lies in its ability to support patients at every stage of their journey. With the acquisition of Ramo Pharm, we are laying the foundations of an ambitious platform, leveraging strong brands and combined expertise to accelerate portfolio growth in Morocco and internationally."
Karim Akouz, Managing Partner of Ramo Pharm, expressed confidence in the partnership: "We built Ramo Pharm with constant rigor, earning the trust of patients and healthcare professionals through quality, efficacy, and innovation. We are convinced that Sothema is the ideal partner to preserve this spirit, sustain this momentum, and give our project a new dimension."
The completion of this transaction remains subject to standard regulatory conditions, including obtaining formal clearance from the Moroccan Competition Council. This acquisition underscores Sothema's commitment to expanding its healthcare footprint beyond its traditional core, utilizing targeted M&A to fuel its local and global ambitions.